This includes: (i) inhibition of ROS production critical for tumor growth and angiogenesis; (ii) inhibition of VEGF production and tumor progression (iii) inhibition of the polarization of M1 phenotype into M2 phenotypes of spleen and peritoneal macrophages in mice bearing EAT, and (iv) immunomodulatory activity as evidenced by the increased M1 tumoricidal efficacy of TAMs and suppressed M2 tumor activity of TAMs. This evidence concerns the gene VEGFA and neoplasm.